- Home
- RLAY vs DRRX Comparison
RLAY vs DRRX Comparison
Compare RLAY & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- DRRX
- Stock Information
- Founded
- RLAY 2015
- DRRX 1998
- Country
- RLAY United States
- DRRX United States
- Employees
- RLAY N/A
- DRRX N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- DRRX Health Care
- Exchange
- RLAY Nasdaq
- DRRX Nasdaq
- Market Cap
- RLAY 576.1M
- DRRX N/A
- IPO Year
- RLAY 2020
- DRRX 2000
- Fundamental
- Price
- RLAY $3.60
- DRRX $0.61
- Analyst Decision
- RLAY Strong Buy
- DRRX Hold
- Analyst Count
- RLAY 11
- DRRX 1
- Target Price
- RLAY $18.40
- DRRX N/A
- AVG Volume (30 Days)
- RLAY 1.5M
- DRRX 47.0K
- Earning Date
- RLAY 08-05-2025
- DRRX 08-12-2025
- Dividend Yield
- RLAY N/A
- DRRX N/A
- EPS Growth
- RLAY N/A
- DRRX N/A
- EPS
- RLAY N/A
- DRRX N/A
- Revenue
- RLAY $7,679,000.00
- DRRX $1,856,000.00
- Revenue This Year
- RLAY $17.59
- DRRX N/A
- Revenue Next Year
- RLAY N/A
- DRRX $673.00
- P/E Ratio
- RLAY N/A
- DRRX N/A
- Revenue Growth
- RLAY N/A
- DRRX 79.84
- 52 Week Low
- RLAY $1.78
- DRRX $0.48
- 52 Week High
- RLAY $10.72
- DRRX $1.74
- Technical
- Relative Strength Index (RSI)
- RLAY 57.25
- DRRX 46.88
- Support Level
- RLAY $3.50
- DRRX $0.57
- Resistance Level
- RLAY $3.86
- DRRX $0.69
- Average True Range (ATR)
- RLAY 0.18
- DRRX 0.06
- MACD
- RLAY 0.02
- DRRX -0.00
- Stochastic Oscillator
- RLAY 65.79
- DRRX 48.12
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).